SOURCE: Medistem Laboratories

February 28, 2007 12:37 ET

Medistem Presents at Regenerative Medicine Organization Conference

Chief of Scientific Development to Give Lecture on Patentability in Biotechnology

SCOTTSDALE, AZ -- (MARKET WIRE) -- February 28, 2007 -- Medistem Laboratories' (OTCBB: MDSM) (FRANKFURT: S2U) Thomas Ichim, Chief of Scientific Development, was invited to talk at the 4th Annual Regenerative Medicine Organization Conference in Las Vegas on the subject of "Intellectual Property in Biotechnology."

"We are honored that the Regenerative Medicine Organization would recognize Thomas as an international leader in the area of intellectual property protection and invite him to address such a distinguished audience as that assembled at the current conference," said Neil Riordan, CEO of Medistem. He continued, "Tom's forward-looking approach to patentability issues, as well as his balanced understanding of science, law and development of therapeutics, is a real asset to Medistem as we seek commercialization of pipeline candidates."

The Regenerative Medicine Conference focus this year is on "The Convergence of Science, Business, Medicine and Politics," and features an array of international opinion leaders. The conference is being held at the Mirage Hotel in Las Vegas from February 26th through February 28th, 2007.

"A great deal of value is lost by scientists not understanding what is and is not patentable," said Thomas Ichim, Medistem's Chief of Scientific Development. "Through enabling scientists and their financial backers to better understand the patent system, what develops is a more productive economic system and as a result society and science move ahead."

A synopsis of the talk may be seen at:

About the Regenerative Medicine Organization

The Regenerative Medicine Organization is a non-profit, educational organization incorporated in the State of Nevada with the purpose of increasing awareness of regenerative medicine and to advance this understanding in the medical, scientific and public communities. It is a clearing house of information on regenerative medicine and treatments, which are discussed at a range of forums and conferences that bring together scientists, researchers and the medical community. Regenerative medicine is the future of health care.

About Medistem Laboratories, Inc.

Medistem Laboratories is an innovative biotechnology company committed to the creation and commercialization of advanced medical therapies based on non-controversial adult stem cells. Medistem's corporate mission is to transform these stem cells into valuable medical treatments. The Company's business strategy calls for the establishment of a series of clinics and laboratories around the world to deliver unprecedented, next-generation cell therapies to help millions of patients while seeking to commercialize products in the U.S. market. Clinic treatments use proprietary technology and cells sourced from umbilical cords, fat, bone marrow, and muscle for the treatment of cerebral palsy, stroke, cardiovascular disease and orthopedic diseases. Medistem believes it may hold a substantial competitive edge in the worldwide emerging market for stem cell-sourced medical solutions, positioning it to become a leading global provider of stem cell treatments on a fee-for-service basis, while accumulating intellectual property based on clinical and laboratory findings.

Cautionary Statement

This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies; operating expenses or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company's products and services; and assumptions relating to the foregoing.

Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.

Some of the important factors that could cause the company's actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs.

These factors are discussed in greater detail in the company's quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission.

Contact Information

  • Contact:
    Medistem Laboratories, Inc.
    Chris McGuinn